Mn Services Vermogensbeheer B.V. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Mn Services Vermogensbeheer B.V. increased its stake in Gilead Sciences by 2.1%, acquiring an additional 9,600 shares, making its total holdings worth approximately $51.67 million.
• Multiple institutional investors bolstered their positions in Gilead, with Price T Rowe Associates growing its stake by 314.6%, now holding shares valued at $1.65 billion.
• Gilead announced a quarterly dividend of $0.79 per share, with an annualized dividend yield of 2.8%, set to be paid on September 29th.

Mn Services Vermogensbeheer B.V. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 466,055 shares of the biopharmaceutical company's stock after purchasing an additional 9,600 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Gilead Sciences were worth $51,672,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at about $25,000. Activest Wealth Management boosted its stake in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new position in Gilead Sciences during the first quarter valued at $29,000. Colonial Trust Advisors lifted its position in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 213 shares in the last quarter. Finally, Core Alternative Capital lifted its position in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded up $0.47 during trading on Friday, reaching $114.09. 12,580,487 shares of the company traded hands, compared to its average volume of 5,841,828. The firm's fifty day simple moving average is $114.10 and its 200 day simple moving average is $110.06. The stock has a market cap of $141.56 billion, a P/E ratio of 22.73, a PEG ratio of 0.77 and a beta of 0.36. Gilead Sciences, Inc. has a 12-month low of $81.83 and a 12-month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company's revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the transaction, the chief financial officer owned 160,110 shares in the company, valued at $18,977,838.30. The trade was a 1.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares of the company's stock, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,390,030 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GILD shares. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Rothschild & Co Redburn upped their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research note on Friday, September 12th. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Finally, Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.